跳转至内容
Merck

P4670

Sigma-Aldrich

普罗帕酮 盐酸盐

别名:

1-[2-(2-Hydroxy-3-(propylamino)propoxy)phenyl]-3-phenyl-1-propanone hydrochloride

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C21H27NO3 · HCl
CAS号:
分子量:
377.90
EC號碼:
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.77

形狀

powder

品質等級

起源

Abbott

儲存溫度

2-8°C

SMILES 字串

Cl[H].CCCNCC(O)COc1ccccc1C(=O)CCc2ccccc2

InChI

1S/C21H27NO3.ClH/c1-2-14-22-15-18(23)16-25-21-11-7-6-10-19(21)20(24)13-12-17-8-4-3-5-9-17;/h3-11,18,22-23H,2,12-16H2,1H3;1H

InChI 密鑰

XWIHRGFIPXWGEF-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

Propafenone hydrochloride is a calcium antagonist. It functions as a Na+ and K+ channel blocker. It might be used to treat patients with systemic hypertension. Propafenone hydrochloride is associated with bradycardia and bronchospasms. It is metabolized in the liver. Propafenone hydrochloride is used to treat ventricular arrhythmias.

應用

Propafenone hydrochloride has been used in the isolation of cardiomyocytes.

生化/生理作用

Blocks hKv1.5 and ATP-sensitive K+ channels; class 1C antiarrhythmic agent that is also an antagonist at β adrenergic receptors.

特點和優勢

This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

象形圖

Exclamation mark

訊號詞

Warning

危險聲明

危險分類

Acute Tox. 4 Oral

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Propafenone hepatotoxicity: report of a new case and review of the literature
Younan LB, et al.
Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association, 19(5), 235-235 (2013)
Pharmacologic management of arrhythmias
Ganjehei L, et al.
Texas Heart Institute Journal, 38(4), 344-344 (2011)
Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study
Opolski G, et al.
Chest, 126(2), 476-486 (2004)
Lori D Bash et al.
Cardiovascular drugs and therapy, 26(2), 167-179 (2012-03-16)
Rate and rhythm control are two well established treatment objectives for atrial fibrillation (AF) patients. While symptom reduction is a primary treatment goal, therapeutic practice related to cardioversion varies by region and patient, with several precautions associated with the use
Alexander Burashnikov et al.
The Journal of pharmacology and experimental therapeutics, 340(1), 161-168 (2011-10-19)
Ranolazine has been shown to produce atrial-selective depression of sodium channel-dependent parameters and suppress atrial fibrillation (AF) in a variety of experimental models. The present study contrasts the effects of ranolazine and those of a clinically used anti-AF class IC

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门